停用联合激素避孕药后雌激素相关血栓生物标志物的纵向变化特征
这项前瞻性队列研究纳入66名决定停用联合激素避孕药(CHC)的18至50岁女性,在停药前及停药后1、2、4、6、12周随访,检测活化蛋白C敏感性比值(nAPCsr)、血栓调节蛋白敏感性比值(nTMsr)及性激素结合球蛋白(SHBG)。从基线至12周,nAPCsr、nTMsr和SHBG平均水平分别从4.11、2.53和167 nmol/L降至1.27、1.11和55.4 nmol/L;相对降幅在停药2周时分别达85.8%、81.3%、76.2%,4周时达86.7%、85.5%、87.8%。作者认为,计划大手术前或静脉血栓栓塞症患者停用抗凝药前停药2至4周对多数女性似乎足够。
要点
- 停用CHC后雌激素相关血栓生物标志物快速下降,2周时已完成大部分降幅。
- nAPCsr、nTMsr及SHBG在停药2周时相对降幅分别为85.8%、81.3%、76.2%。
- 作者认为计划大手术前或VTE患者停抗凝前停药2至4周对多数女性似乎足够。
核心结论
- 停用CHC后雌激素相关血栓生物标志物快速下降。
- 计划大手术前或VTE患者停用抗凝药前停药2至4周对多数女性似乎足够。
研究设计与样本
- 前瞻性队列研究,纳入66名决定停用CHC的18至50岁女性,排除有VTE个人史、抗凝治疗或妊娠者。
- 研究于停用CHC前开始,停药后随访6次(停药后1、2、4、6、12周)。
- 另纳入28名未使用CHC的对照女性。
- 主要结局为活化蛋白C敏感性比值(nAPCsr)和血栓调节蛋白敏感性比值(nTMsr),性激素结合球蛋白(SHBG)为次要终点。
- 试验注册号NCT03949985。
主要发现
- 66名CHC使用者从基线至12周,nAPCsr平均水平从4.11(标准差2.06)降至1.27(标准差0.82)。
- nTMsr平均水平从2.53(标准差1.03)降至1.11(标准差0.58)。
- SHBG平均水平从167 nmol/L(标准差103)降至55.4 nmol/L(标准差26.7)。
- 相对降幅在停药2周时nAPCsr为85.8%、nTMsr为81.3%、SHBG为76.2%,停药4周时分别为86.7%、85.5%、87.8%。
- 28名对照女性研究期间水平无有意义的改变。
临床怎么用
- 作者认为,计划大手术前或VTE患者停用抗凝药前停药2至4周对多数女性似乎足够。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The persistence of risk of venous thromboembolism (VTE) due to combined hormonal contraceptives (CHCs), after their cessation, is unknown but important to guide clinical practice. The objective of this prospective cohort study was to define the time until normalization of estrogen-related thrombotic biomarkers after CHC cessation. We enrolled women aged 18 to 50 years who had decided to stop their CHC, excluding those with a personal history of VTE, anticoagulation, or pregnancy. The study started before cessation of CHC, with 6 visits afterwards (at 1, 2, 4, 6, and 12 weeks after cessation). Primary outcomes were normalized sensitivity ratios to activated protein C (nAPCsr) and to thrombomodulin (nTMsr), with sex hormone-binding globulin (SHBG) as a secondary end point. We also included control women without CHC. Among 66 CHC users, from baseline until 12 weeks, average levels of nAPCsr, nTMsr, and SHBG decreased from 4.11 (standard deviation [SD], 2.06), 2.53 (SD, 1.03), and 167 nmol/L (SD, 103) to 1.27 (SD, 0.82), 1.11 (SD, 0.58), and 55.4 nmol/L (SD, 26.7), respectively. On a relative scale, 85.8%, 81.3%, and 76.2% of the decrease from baseline until 12 weeks was achieved at 2 weeks and 86.7%, 85.5%, and 87.8% at 4 weeks after CHC cessation, respectively. Levels were not meaningfully modified throughout the study period among 28 control women. In conclusion, CHC cessation is followed by a rapid decrease in estrogen-related thrombotic biomarkers. Two to 4 weeks of cessation before planned major surgery or withdrawal of anticoagulants in patients with VTE appears sufficient for the majority of women. The trial is registered at www.clinicaltrials.gov as #NCT03949985.
引用
- Hugon-Rodin J, Fontana P, Poncet A, et al. Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives. Blood. 2024. PMID: 37939264. doi:10.1182/blood.2023021717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。